9-methyl-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one | 57368-87-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 9-methyl-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one
• 英文别名: 7-Methyl-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-2-one；7-methyl-1-azatricyclo[7.3.1.05,13]trideca-5,7,9(13)-trien-2-one
• CAS: 57368-87-3
• 化学式: C₁₃H₁₅NO
• 分子量: 201.268
• InChiKey: SXTYFWSEMMVEJT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-pent-4-enoyl-3-propargylpiperidin-2-one 在 对甲苯磺酸 作用下， 以 邻二氯苯 为溶剂， 反应 3.0h， 以31%的产率得到9-methyl-1,2,6,7-tetrahydro-5H-pyrido[3,2,1-ij]quinolin-3-one
  参考文献：
  名称：

  Gold- and Silver-Mediated Cycloisomerizations of N-Propargylamides

  摘要：

  Substituted N-propargylamides have proven to be valuable substrates for alkyne-activated cycloisomerization reactions. N-Tosyl-N'-propargylurea underwent reaction with AuCl3 to give the corresponding dihydroimidazolone, while N-propargyl-3-oxobutanamides and esters were used to construct furanyl fused pyrrolldinones and dihydrofuranones via Ag(I)-mediated alkyne activation.

  DOI：

  10.1021/ol801847j

文献信息

• RADIOACTIVE QUINOLINONE DERIVATIVE AND PHARMACEUTICAL DRUG COMPRISING THE SAME
  申请人：Nihon Medi-Physics Co., Ltd.

  公开号：US20140187784A1

  公开（公告）日：2014-07-03

  It is intended to provide a radioactive compound that has higher selectivity for CYP11B2 than that for CYP11B1, exhibits highly selective accumulation in the adrenal gland compared with blood and organs adjacent to the adrenal gland, and permits commercial supply. The present invention provides a radioactive quinolinone derivative represented by the predetermined general formula or a salt thereof.

  本发明旨在提供一种放射性化合物，其对CYP11B2的选择性高于对CYP11B1的选择性，与血液和邻近肾上腺器官相比，在肾上腺腺体中表现出高度选择性的积累，并且可以进行商业供应。本发明提供了由预定一般式表示的放射性喹啉酮衍生物或其盐。
• Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1891954A2

  公开（公告）日：2008-02-27

  The invention relates to a compound of the formula or a salt thereof for improving excretory potency of the urinary bladder, such as for treating or preventing dysuria and for treating or preventing difficulty of urination. The invention further relates to a pharmaceutical composition comprising said compound.

  本发明涉及一种式如下的化合物 或其盐，用于改善膀胱的排泄能力，如治疗或预防排尿困难以及治疗或预防排尿困难。本发明还涉及一种包含上述化合物的药物组合物。
• Gold- and Silver-Mediated Cycloisomerizations of <i>N</i>-Propargylamides
  作者：Guido Verniest、Albert Padwa

  DOI：10.1021/ol801847j

  日期：2008.10.2

  Substituted N-propargylamides have proven to be valuable substrates for alkyne-activated cycloisomerization reactions. N-Tosyl-N'-propargylurea underwent reaction with AuCl3 to give the corresponding dihydroimidazolone, while N-propargyl-3-oxobutanamides and esters were used to construct furanyl fused pyrrolldinones and dihydrofuranones via Ag(I)-mediated alkyne activation.